http://annonc.oxfordjournals.org/cgi...nt/full/mdp322
Of interest:
"anti-HER2 therapy
Updated results from two of the trastuzumab trials were presented
continuing to demonstrate the value of this therapy for patients
with HER2-positive disease. The FinHER trial evaluated a short
course of trastuzumab, which is currently being compared with
a conventional 1-year duration. Meanwhile, the standard duration
of trastuzumab therapy remains 1 year. The Panel noted that
no results are yet available from the 2-year trastuzumab group
in the HERA trial.
Interestingly, a majority of the Panel was prepared, for selected women, to contemplate trastuzumab with endocrine therapy but without chemotherapy despite the absence of clinical trial evidence to support this approach. Finally,
the limited evidence of increased risk among patients with HER2-positive
tumours <1 cm in size without axillary nodal involvement
does not allow definitive recommendation regarding anti-HER2
therapy in this group.
" (emphasis added)
May I add, the majority of the panel rocks!
Hopeful